Share Price, Speaker Panel, and News Sightings…

Our Tier 3 of 30,000 shares is nearly full and we will pause our Stock Offering on Tuesday, November 27, 2018. At that time we plan on submitting a new price and valuation to the SEC for qualification. Upon approval of the updated Stock Offering, we anticipate our offering will again be available for purchase in January, 2019. During the pause we’ll be taking reservations for the new share price.

In case you’ve missed it, our pricing and investments since July 17th are as follows:

Tier 1: 100% Filled at $5.75 Share Price | 275,661 Shares

Tier 2: 100% Filled at $6.85 Share Price | 43,126 Shares

Tier 3: 81% Filled at $6.90 Share Price | 30,000 Shares Available; [Paused on Tuesday, Nov. 27th]

Dr. Daniel Sipple will be at the 2018 G20 World Brain Mapping Therapeutics Summit in Buenos Aires, presenting on November 26th. The Summit aims to contribute to President Obama’s BRAIN initiative and to expand action on the current and upcoming initiatives across the G20 nations. Dr. Sipple will be a representative on the Brain and Spine Trauma and Opioid Crisis panel.

More props to Dr. Sipple with his mention in the Northwestern Medicine Magazine.

Dr. Jake Hutchins was interviewed about the newly FDA cleared drug, Dsuvia. Dsuvia, an opioid-based painkiller, has been a controversial FDA clearance. We agree with Dr. Jake Hutchins that “Dsuvia fills a gap that we don’t have anything else to fill with”. The full story and interview:

MedCityNews, a leading healthcare innovation news source, interviewed us for their “Founders Story”:

We will continue to report to you on a regular basis, however, please do not hesitate to drop me a line with any questions or comments. We remain focused on getting to Phase 1 with the best possible product. We expect our non-opiate, AnestaGel to be proven safe, fast acting, long lasting, injectable and smearable.

Leave a Reply

Your email address will not be published. Required fields are marked *